Ismael A. Rocha-Da Costa

Belo Horizonte, MG, Brazil

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

The dialog between mother and newborn: insights from immune mediator crosstalk elicited by antenatal SARS-COV-2 exposure.

The dialog between mother and newborn: insights from immune mediator crosstalk elicited by antenatal SARS-COV-2 exposure.

Journal: Frontiers in immunology

Published: April 05, 2025

IL-17 as a putative hallmark of intense arthralgia and age-related serum immune mediator networks during acute chikungunya fever.

IL-17 as a putative hallmark of intense arthralgia and age-related serum immune mediator networks during acute chikungunya fever.

Journal: Inflammation research : official journal of the European Histamine Research Society ... [et al.]

Published: August 02, 2024

Hydroxychloroquine is associated with lower seroconversion upon 17DD-Yellow fever primovaccination in patients with primary Sjögren's syndrome.

Hydroxychloroquine is associated with lower seroconversion upon 17DD-Yellow fever primovaccination in patients with primary Sjögren's syndrome.

Journal: Human vaccines & immunotherapeutics

Published: July 04, 2024

MR1 blockade drives differential impact on integrative signatures based on circuits of circulating immune cells and soluble mediators in visceral leishmaniasis.

MR1 blockade drives differential impact on integrative signatures based on circuits of circulating immune cells and soluble mediators in visceral leishmaniasis.

Journal: Frontiers in immunology

Published: January 19, 2024

Timeline kinetics of protective immunity to SARS-CoV-2 upon primary vaccination and humoral response to variants after booster dose.

Timeline kinetics of protective immunity to SARS-CoV-2 upon primary vaccination and humoral response to variants after booster dose.

Journal: Vaccine

Published: April 24, 2023

Panoramic snapshot of serum soluble mediator interplay in pregnant women with convalescent COVID-19: an exploratory study.

Panoramic snapshot of serum soluble mediator interplay in pregnant women with convalescent COVID-19: an exploratory study.

Journal: Frontiers in immunology

Published: March 01, 2023

Serum soluble mediators as prognostic biomarkers for morbidity, disease outcome, and late-relapsing hepatitis in yellow fever patients.

Serum soluble mediators as prognostic biomarkers for morbidity, disease outcome, and late-relapsing hepatitis in yellow fever patients.

Journal: Clinical immunology (Orlando, Fla.)

Published: December 21, 2022

Serum Soluble Mediator Profiles and Networks During Acute Infection With Distinct DENV Serotypes.

Serum Soluble Mediator Profiles and Networks During Acute Infection With Distinct DENV Serotypes.

Journal: Frontiers in immunology

Published: March 09, 2022

Phenotypic and Functional Signatures of Peripheral Blood and Spleen Compartments of Cynomolgus Macaques Infected With T. cruzi: Associations With Cardiac Histopathological Characteristics.

Phenotypic and Functional Signatures of Peripheral Blood and Spleen Compartments of Cynomolgus Macaques Infected With T. cruzi: Associations With Cardiac Histopathological Characteristics.

Journal: Frontiers in cellular and infection microbiology

Published: April 28, 2021

Serum biomarker profile orchestrating the seroconversion status of patients with autoimmune diseases upon planned primary 17DD Yellow fever vaccination.

Serum biomarker profile orchestrating the seroconversion status of patients with autoimmune diseases upon planned primary 17DD Yellow fever vaccination.

Journal: Scientific reports

Published: December 14, 2020

Planned Yellow Fever Primary Vaccination Is Safe and Immunogenic in Patients With Autoimmune Diseases: A Prospective Non-interventional Study.

Planned Yellow Fever Primary Vaccination Is Safe and Immunogenic in Patients With Autoimmune Diseases: A Prospective Non-interventional Study.

Journal: Frontiers in immunology

Published: March 08, 2020

Corrigendum: Duration of Humoral and Cellular Immunity 8 Years After Administration of Reduced Doses of the 17DD-Yellow Fever Vaccine.

Corrigendum: Duration of Humoral and Cellular Immunity 8 Years After Administration of Reduced Doses of the 17DD-Yellow Fever Vaccine.

Journal: Frontiers in immunology

Published: September 09, 2019

Showing 1-12 of 15

Last Updated: 09/26/2026